Trial Profile

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JR-446 (Primary)
Indications Mucopolysaccharidosis III
Focus Adverse reactions; Therapeutic Use
Sponsors JCR Pharmaceuticals

Most Recent Events

03 Feb 2025 Planned End Date changed from 30 Sep 2029 to 5 Dec 2028.
03 Feb 2025 Planned primary completion date changed from 31 Mar 2027 to 5 Jun 2026.
05 Dec 2024 According to a JCR Pharmaceuticals media release, Dr. Motomichi Kosuga, Medical Director of the Division of Medical Genetics, National Center for Child Health and Development, is the Medical Expert of the study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com